{"id":"W3185777435","doi":"10.1158/1078-0432.ccr-21-0310","title":"Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study","year":2021,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kelowna General Hospital; Institute of Cancer Research","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Eisai; Cancer Research UK; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; National Cancer Research Institute; GlaxoSmithKline; Celgene; Amgen; University of Texas MD Anderson Cancer Center; Pfizer; MacroGenics; Cancer Research Institute","keywords":"Breast cancer; Oncology; Medicine; Germline; Internal medicine; Cancer; Germline mutation; Mutation; Genetics; Biology; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001515594,0.0006024316,0.001202569,0.0001607735,0.000167596,0.0009213577,0.0007134417,0.0006904898,0.001816687],"category_scores_gemma":[0.0006957873,0.0003271527,0.001091601,0.0002605163,0.0004683526,0.0003412811,0.0002723771,0.001330084,0.0004734466],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005620047,"about_ca_system_score_gemma":0.0008009077,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001103893,"about_ca_topic_score_gemma":0.003561263,"domain_scores_codex":[0.9994154,0.0003404533,0.00002464312,0.00007560554,0.00007176501,0.00007214875],"domain_scores_gemma":[0.9995891,0.00008028453,0.00008675457,0.00005570877,0.00003275259,0.0001553115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8226325,0.01399072,0.02844333,0.001560456,0.00376672,0.0003108253,0.0001535296,0.002234342,0.02742498,0.0004914352,0.006006351,0.09298488],"study_design_scores_gemma":[0.770232,0.131515,0.07561494,0.0003059919,0.003466824,0.0009322628,0.0001066648,0.001634951,0.003533775,0.0006096206,0.01199413,0.00005396627],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818808,0.01113297,0.0003668913,0.0004947011,0.0001930641,0.0008614685,0.00117565,0.0000319988,0.003862513],"genre_scores_gemma":[0.9911494,0.002850943,0.0005115897,0.0008658608,0.0001835437,0.000543179,0.002060189,0.0000170635,0.001818291],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001816687,"threshold_uncertainty_score":0.008015335,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2235213596073076,"score_gpt":0.525599806114159,"score_spread":0.3020784465068514,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}